• 1-(844)-30-STOCK

Need updates On Your Mobile Text STOCKS to 67076

BioPharma

Non-systemic, yeast-derived recombinant enzyme Lipase Treatment

Stock Profile Report -- AZRX


Stock Profile Report–AZRX

This is the story of $1.5 Billion… In a Winner-Take-All Game… And Why We Think that Game (and that $1.5 Billion)Will Mostly Benefit Investors in Just One Stock:

AZRX

CashRain

This particular $1.5B is the size of the global market for treating exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP) and cystic fibrosis (CF).

This story is actually a “Winner Take All” game:  Whoever can deliver the best treatment takes home the prize!

Until recently, that prize looked like it was going to go to Anthera (ANTH). Anthera had a phase III trial underway…BUT they didn’t get the results they were hoping for (the ANTH phase III primary endpoint was NOT MET). That result opened the door for the rest of the field. And now…

THE RACE IS ON

Spoiler Alert:The Race May End with Investors in One New Biotech Living Happily Ever After…

AzurRxBioPharma Inc. (AZRX)

Logo

  • Shares Outstanding: Less than 10 Million
  • Trading Float: Less than 3 Million              

The Reason Why Anthera Failed is Also the Reason Why AZRX is Now Suddenly the Most Likely Winner-in-waiting. And yet, very few people have put this together, so…

StillTime

AZRX solved the problem by starting with molecules that can stand up the acidic environment that we all have in our Gut. That means:

  • FEWER PILLS
  • MORE EFFICACY
  • EASIER DOSING
  • HAPPIER PATIENTS
  • GREATER LIKELIHOOD OF TRIAL SUCCESS

This is all thanks to a Revolutionary idea:

“Non-systemic, yeast-derived recombinant enzyme Lipase Treatment”

Lipase

The Board and Science Team at AZRX has Over 165 Years of Combined Experience in Biotechnology and Medical Science, Headed by a CEO who is a Former Top JPMorgan Analyst

AzurRxBioPharma Inc. (AZRX)

Logo

This Company has One More Special Advantage:

RESEARCH ->Done in FranceBUSINESS ->Run in the USA

Flags

CapitalEfficiency

It’s the Best of Both Worlds! And this means BIG BUCKS for AZRX Investors

 AzurRxBioPharma Inc. (AZRX)

AZRX Summary

So… What’s Next?

AZRX is now in Phase IIa Trial… Results Will Start to Indicate Efficacy Soon. At that Point, this Stock Could be “Discovered” by the World in a Hurry.

 When that happens… Remember: Float is Tiny at Just 2.88 Million Shares.

It Might be Tough to Catch!

 BUT… Right Now:

DESCLAIMER

General Notice and Disclaimer – PLEASE READ CAREFULLY

THE FOLLOWING NOTICE AND DISCLAIMER MUST BE READ AND UNDERSTOOD AND YOU MUST AGREE TO THE TERMS CONTAINED THEREIN BEFORE USING THIS WEBSITE OR SUBSCRIBING TO OUR NEWSLETTER…

MyBestStockPicks engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Our Newsletter nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Our Newsletter. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk… Read More

Total Views: 401 ,